PET in prostate and bladder tumors

Seminars in Nuclear Medicine

Volumn 42, Issue 4, 2012, Pages 231-246

  Lee, Sze Ting ^a,b,c   Lawrentschuk, Nathan ^b,c   Scott, Andrew M ^a,b,c  

^a AUSTIN HOSPITAL   (Australia)

^b OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID C 11; CHOLINE C 11; CHOLINE F 18; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; IODINE 124; MEDRONATE TECHNETIUM TC 99M; METHIONINE C 11; OXIDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRACER; UNCLASSIFIED DRUG;

ADVANCED CANCER; BLADDER CARCINOMA; BONE METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; DIURESIS; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MEDICAL DECISION MAKING; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROGNOSIS; PROSTATE CARCINOMA; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; URETER CANCER; URETER CARCINOMA; URETHRA CANCER; URETHRA CARCINOMA; URINARY EXCRETION;

HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; URINARY BLADDER NEOPLASMS;

EID: 84861961668     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2012.03.002     Document Type: Review

References (118)

1. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
2. Fuchsjäger M, Shukla-Dave A, Akin O, et al: Prostate cancer imaging. Acta Radiol 2008;49:107-120
3. Terris MK, Stamey TA: Determination of prostate volume by transrectal ultrasound. J Urol 1991;145:984-987
4. Kravchick S, Cytron S, Peled R, et al: Using gray-scale and two different techniques of color Doppler sonography to detect prostate cancer. Urology 2003;61:977-981 (Pubitemid 36547742)
5. Kravchick S, Cytron S, Peled R, et al: Optimal combinations for detection of prostate cancer: Systematic sextant and laterally directed biopsies versus systematic sextant and color Doppler-targeted biopsies. Urology 2004;63:301-305 (Pubitemid 38234423)
6. Fütterer JJ, Barentsz J, Heijmijnk ST: Imaging modalities for prostate cancer. Expert Rev Anticancer Ther 2009;9:923-937
7. Phipps S, Yang TH, Habib FK, et al: Measurement of tissue mechanical characteristics to distinguish between benign and malignant prostatic disease. Urology 2005;66:447-450 (Pubitemid 41138122)
8. Prando A, Wallace S: Helical CT of prostate cancer: Early clinical experience. Am J Roentgenol 2000;175:343-346 (Pubitemid 30619178)
9. Ives EP, Burke MA, Edmonds PR, et al: Quantitative computed tomography perfusion of prostate cancer: Correlation with whole-mount pathology. Clin Prostate Cancer 2005;4:109-112 (Pubitemid 41474605)
10. Harisinghani MG, Barentsz J, Hahn PF, et al: Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491-2499 (Pubitemid 36706536)
11. Villeirs GM, Oosterlinck W, Vanherreweghe E, et al: A qualitative approach to combined magnetic resonance imaging and spectroscopy in the diagnosis of prostate cancer. Eur J Radiol 2010;73:352-356
12. Hara N, Okuizumi M, Koike H, et al: Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 2005;62:140-147 (Pubitemid 40096780)
13. Engelbrecht MR, Jager GJ, Laheij RJ, et al: Local staging of prostate cancer using magnetic resonance imaging: A meta-analysis. Eur Radiol 2002;12:2294-2302 (Pubitemid 36940327)
14. Sonnad SS, Langlotz CP, Schwartz JS: Accuracy of MR imaging for staging prostate cancer: A meta-analysis to examine the effect of technologic change. Acad Radiol 2001;8:149-157 (Pubitemid 32666473)
15. Raz O, Haider M, Trachtenberg J, et al: MRI for men undergoing active surveillance or with rising PSA and negative biopsies. Nat Rev Urol 2010;7:543-551
16. Haider MA, Chung P, Sweet J, et al: Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:425-430
17. Rouvière O, Valette O, Grivolat S, et al: Recurrent prostate cancer after external beam radiotherapy: Value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor - Correlation with biopsy findings. Urology 2004;63:922-927 (Pubitemid 38596680)
18. Sciarra A, Panebianco V, Salciccia S, et al: Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol 2008;54:589-600
19. Scheidler J, Hricak H, Vigneron DB, et al: Prostate cancer: Localization with three-dimensional proton MR spectroscopic imaging - Clinico-pathologic study. Radiology 1999;213:473-480 (Pubitemid 29510595)
20. Zakian KL, Sircar K, Hricak H, et al: Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005;234:804-814 (Pubitemid 40250824)
21. Margel D, Yap SA, Lawrentschuk N, et al: Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: A prospective cohort study. J Urol 2012;187:1247-1252
22. Lawrentschuk N, Davis ID, Bolton DM, et al: Positron emission tomography and molecular imaging of the prostate: An update. BJU Int 2006;97:923-931
23. Macheda ML, Rogers S, Best JD: Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202:654-662 (Pubitemid 40175840)
24. Smith TA: Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci 2000;57:170-178
25. Jadvar H, Xiankui L, Shahinian A, et al: Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging 2005;4:91-97 (Pubitemid 43143795)
26. 18fluorine- labeled deoxyglucose. J Urol 1996;155:994-998
27. Haseman MK, Reed NL, Rosenthal SA: Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. Clin Nucl Med 1996;21:704-713 (Pubitemid 26303725)
28. Shreve PD, Grossman HB, Gross MD, et al: Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996;199:751-756
29. Oyama N, Akino H, Suzuki Y, et al: The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 1999;29:623-629
30. Liu IJ, Zafar MB, Lai YH, et al: Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001;57:108-111 (Pubitemid 32065829)
31. Oyama N, Akino H, Suzuki Y, et al: Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol Imaging Biol 2002;4:99-104 (Pubitemid 34272714)
32. Morris MJ, Akhurst T, Osman I, et al: Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002;59:913-918 (Pubitemid 34522186)
33. Minamimoto R, Uemura H, Sano F, et al: The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level. Ann Nucl Med 2011;25:21-27
34. Hofer C, Laubenbacher C, Block T, et al: Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol 1999;36:31-35 (Pubitemid 29265277)
35. Oyama N, Akino H, Suzuki Y, et al: FDG-PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl Med Commun 2001;22:963-969 (Pubitemid 32783446)
36. Chang CH, Wu HC, Tsai JJ, et al: Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int 2003;70:311-315 (Pubitemid 36566263)
37. Jadvar H, Pinski JK, Conti PS: FDG-PET in suspected recurrent and metastatic prostate cancer. Oncol Rep 2003;10:1485-1488
38. Schöder H, Herrmann K, Gönen M, et al: 2-[18F]fluoro-2- deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 2005;11:4761-4769 (Pubitemid 41557196)
39. Jadvar H: Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med 2011;52:81-89
40. Mathews D, Oz OK: Positron emission tomography in prostate and renal cell carcinoma. Curr Opin Urol 2002;12:381-385
41. Sung J, Espiritu JI, Segall GM, et al: Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer. BJU Int 2003;92:24-27 (Pubitemid 36843022)
42. Hillner BE, Siegel BA, Shields AF, et al: Relationship between cancer type and impact of PET and PET/CT on intended management: Findings of the national oncologic PET registry. J Nucl Med 2008;49:1928-1935
43. Heidenreich A, Bellmunt J, Bolla M, et al: EAU guidelines on prostate cancer. part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71
44. Mohler JL, The NCCN Prostate Cancer Panel Members: National Comprehensive Cancer Network Guidelines Prostate Cancer Version 1. 2012
45. Morris MJ, Akhurst T, Larson SM, et al: Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 2005;11:3210-3216 (Pubitemid 40627867)
46. Jadvar H: Molecular imaging of prostate cancer with 18F- fluorodeoxyglucose PET. Nat Rev Urol 2009;6:317-323
47. Scher B, Seitz M, Albinger W, et al: Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging 2007;34:45-53 (Pubitemid 44885553)
48. de Jong IJ, Pruim J, Elsinga PH, et al: Visualisation of bladder cancer using (11)C-choline PET: First clinical experience. Eur J Nucl Med Mol Imaging 2002;29:1283-1288 (Pubitemid 44392207)
49. de Jong IJ, Pruim J, Elsinga PH, et al: Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol 2002;42:18-23 (Pubitemid 35345101)
50. Oyama N, Akino H, Kanamaru H, et al: 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002;43:181-186 (Pubitemid 34151040)
51. Sutinen E, Nurmi M, Roivainen A, et al: Kinetics of [(11)C]choline uptake in prostate cancer: A PET study. Eur J Nucl Med Mol Imaging 2004;31:317-324 (Pubitemid 38314074)
52. Farsad M, Schiavina R, Castellucci P, et al: Detection and localization of prostate cancer: Correlation of (11)C-choline PET/CT with histopathologic step-section analysis. J Nucl Med 2005;46:1642-1649 (Pubitemid 46211588)
53. Testa C, Schiavina R, Lodi R, et al: Prostate cancer: Sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology 2007;244:797-806 (Pubitemid 47292091)
54. Giovacchini G, Picchio M, Briganti A, et al: [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol 2010;184:938-943
55. Giovacchini G, Picchio M, Coradeschi E, et al: Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010;37:301-309
56. Reske SN, Blumstein NM, Glatting G: [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008;35:9-17 (Pubitemid 350234137)
57. Rinnab L, Mottaghy FM, Simon J, et al: [11C]choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int 2008;81:191-197
58. Schiavina R, Scattoni V, Castellucci P, et al: 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: Comparison with clinical staging nomograms. Eur Urol 2008;54: 392-401
59. Rinnab L, Blumstein NM, Mottaghy FM, et al: 11C-choline positronemission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int 2007;99: 1421-1426 (Pubitemid 47164799)
60. Rinnab L, Mottaghy FM, Blumstein NM, et al: Evaluation of [11C]- choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007;100:786-793 (Pubitemid 47360183)
61. Castellucci P, Fuccio C, Nanni C, et al: Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009;50:1394-1400
62. Richter JA, Rodríguez M, Rioja J, et al: Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Mol Imaging Biol 2010;12:210-217
63. Chang JH, Joon DL, Lee ST, et al: Histopathological correlation of (11)C-choline PET scans for target volume definition in radical prostate radiotherapy. Radiother Oncol 2011;99:187-192
64. Price DT, Coleman RE, Liao RP, et al: Comparison of 18F-fluorocholine and 18F-fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002;168:273-280 (Pubitemid 34640843)
65. Igerc I, Kohlfürst S, Gallowitsch HJ, et al: The value of 18F-choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. Eur J Nucl Med Mol Imaging 2008;35:976-983
66. Bauman G, Belhocine T, Kovacs M, et al: (18)F-fluorocholine for prostate cancer imaging: A systematic review of the literature. Prostate Cancer Prostatic Dis 2012;15:45-55
67. Beheshti M, Langsteger W, Fogelman I: Prostate cancer: Role of SPECT and PET in imaging bone metastases. Semin Nucl Med 2009;39:396-407
68. Pinkawa M, Piroth MD, Holy R, et al: Dose-escalation using intensity-modulated radiotherapy for prostate cancer-Evaluation of quality of life with and without 18F-choline PET-CT detected simultaneous integrated boost. Radiol Oncol 2012;7:14
69. Kato T: Evaluation of physiological accumulation of [11C]acetate in normal prostate using positron emission tomography [in Japanese]. Hokkaido Igaku Zasshi 2002;77:359-365
70. Kato T, Tsukamoto E, Kuge Y, et al: Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: Comparison with prostate cancer. Eur J Nucl Med Mol Imaging 2002;29:1492-1495 (Pubitemid 35232052)
71. Mena E, Turkbey B, Mani H, et al: 11C-acetate PET/CT in localized prostate cancer: A study with MRI and histopathologic correlation. J Nucl Med 2012;53(4):538-545
72. Oyama N, Miller TR, Dehdashti F, et al: 11C-acetate PET imaging of prostate cancer: Detection of recurrent disease at PSA relapse. J Nucl Med 2003;44:549-555 (Pubitemid 39663421)
73. Sandblom G, Dufmats M, Olsson M, et al: Validity of a population-based cancer register in Sweden - An assessment of data reproducibility in the south-east region prostate cancer register. Scand J Urol Nephrol 2003;37:112-119 (Pubitemid 36535228)
74. Fricke E, Machtens S, Hofmann M, et al: Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging 2003;30:607-611 (Pubitemid 36559841)
75. Larson SM, Morris M, Gunther I, et al: Tumor localization of 16beta-18F-fluoro- 5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004;45:366-373 (Pubitemid 47618608)
76. Fox JJ, Morris MJ, Larson SM, et al: Developing imaging strategies for castration resistant prostate cancer. Acta Oncol 2011;50(suppl 1):39-48
77. Bouchelouche K, Turkbey B, Choyke P, et al: Imaging prostate cancer: An update on positron emission tomography and magnetic resonance imaging. Curr Urol Rep 2010;11:180-190
78. Afshar-Oromieh A, Haberkorn U, Eder M, et al: [(68)Ga]gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: Comparison with (18)F-FECH. Eur J Nucl Med Mol Imaging 2012 Feb 4 [Epub ahead of print]
79. Hillier SM, Maresca KP, Femia FJ, et al: Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009;69:6932-6940
80. Elsässer-Beile U, Reischl G, Wiehr S, et al: PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med 2009;50:606-611
81. Lawrentschuk N, Davis ID, Bolton DM, et al: Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: Current practice. Int J Urol 2007;14:89-95 (Pubitemid 46121943)
82. Peterson JJ, Kransdorf MJ, O'Connor MI: Diagnosis of occult bone metastases: Positron emission tomography. Clin Orthop Relat Res 2003:S120-S128 (Pubitemid 37323328)
83. Kanamaru H, Oyama N, Akino H, et al: [Evaluation of prostate cancer using FDG-PET]. Hinyokika Kiyo 2000;46:851-853
84. Li Y, Schiepers C, Lake R, et al: Clinical utility of (18)F-fluoride PET/CT in benign and malignant bone diseases. Bone 2012;50:128-139
85. Even-Sapir E, Metser U, Flusser G, et al: Assessment of malignant skeletal disease: Initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 2004;45:272-278 (Pubitemid 47618648)
86. Even-Sapir E, Metser U, Mishani E, et al: The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006;47:287-297 (Pubitemid 46780894)
87. Beheshti M, Vali R, Waldenberger P, et al: Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: A comparative study. Eur J Nucl Med Mol Imaging 2008;35:1766-1774
88. Beheshti M, Vali R, Langsteger W: [18F]fluorocholine PET/CT in the assessment of bone metastases in prostate cancer. Eur J Nucl Med Mol Imaging 2007;34:1316-1317; author reply 1318-1319
89. Picchio M, Spinapolice EG, Fallanca F, et al: [11C]choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: Comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 2012;39:13-26
90. Beheshti M, Langsteger W: Choline PET/CT compared with bone scintigraphy in the detection of bone metastases in prostate cancer patients. Eur J Nucl Med Mol Imaging 2012 Jan 19 [Epub ahead of print]
91. Kaufman DS, Shipley WU, Feldman AS: Bladder cancer. Lancet 2009; 374:239-249
92. Lu YY, Chen JH, Liang JA, et al: Clinical value of FDG-PET or PET/CT in urinary bladder cancer: A systemic review and meta-analysis. Eur J Radiol 2011 Sep 5 [Epub ahead of print]
93. Paik ML, Scolieri MJ, Brown SL, et al: Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol 2000;163:1693-1696 (Pubitemid 30366715)
94. Shvarts O, Han KR, Seltzer M, et al: Positron emission tomography in urologic oncology. Cancer Contr 2002;9:335-342 (Pubitemid 34921039)
95. Sadow CA, Silverman SG, O'Leary MP, et al: Bladder cancer detection with CT urography in an academic medical center. Radiology 2008;249:195-202
96. Kim B, Semelka RC, Ascher SM, et al: Bladder tumor staging: Comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology 1994;193:239-245
97. Anjos DA, Etchebehere EC, Ramos CD, et al: 18F-FDG-PET/CT delayed images after diuretic for restaging invasive bladder cancer. J Nucl Med 2007;48:764-770 (Pubitemid 47604977)
98. Kosuda S, Kison PV, Greenough R, et al: Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med 1997;24:615-620 (Pubitemid 27299740)
99. Bachor R, Kotzerke J, Reske SN, et al: Lymph node staging of bladder neck carcinoma with positron emission tomography [in German]. Urologe A 1999;38:46-50 (Pubitemid 29146329)
100. Drieskens O, Oyen R, Van Poppel H, et al: FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 2005;32:1412-1417 (Pubitemid 41746845)
101. Kibel AS, Dehdashti F, Katz MD, et al: Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol 2009;27:4314-4320
102. Apolo AB, Riches J, Schöder H, et al: Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol 2010;28:3973-3978
103. Jadvar H, Quan V, Henderson RW, et al: [F-18]-fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol 2008;13:42-47 (Pubitemid 351326281)
104. Harkirat S, Anand S, Jacob M: Forced diuresis and dual-phase F-fluorodeoxyglucose- PET/CT scan for restaging of urinary bladder cancers. Indian J Radiol Imaging 2010;20:13-19
105. Clark PE, The NCCN Bladder Cancer Panel Members: National Comprehensive Cancer Network Guidleines Bladder Cancer Version 2. Available at: http://www.nccn.org. Accessed 2012
106. Stenzl A, Cowan NC, De Santis M, et al: The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009;55:815-825
107. Patil VV, Wang ZJ, Sollitto RA, et al: 18F-FDG-PET/CT of transitional cell carcinoma. Am J Roentgenol 2009;193:W497-W504
108. Heicappell R, Müller-Mattheis V, Reinhardt M, et al: Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose. Eur Urol 1999;36:582-587 (Pubitemid 29516289)
109. Schirrmeister H, Guhlmann A, Kotzerke J, et al: Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999;17:2381-2389 (Pubitemid 29368236)
110. Powles T, Murray I, Brock C, et al: Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur Urol 2007;51:1511-1520; discussion 1520-1511
111. Ahlström H, Malmström PU, Letocha H, et al: Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol 1996;37:180-185 (Pubitemid 126710100)
112. Bouchelouche K, Oehr P: Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: An update review. J Urol 2008;179:34-45 (Pubitemid 350225698)
113. Jana S, Blaufox MD: Nuclear medicine studies of the prostate, testes, and bladder. Semin Nucl Med 2006;36:51-72 (Pubitemid 41779367)
114. Picchio M, Treiber U, Beer AJ, et al: Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: Correlation with histopathologic findings. J Nucl Med 2006;47:938-944 (Pubitemid 46939945)
115. Gofrit ON, Mishani E, Orevi M, et al: Contribution of 11C-choline positron emission tomography/computerized tomography to preoperative staging of advanced transitional cell carcinoma. J Urol 2006;176:940-944; discussion 944
116. Dou Y, Pinkus E, Girshovich L: Impact of FDG-PET/CT on the decision making of initial treatment of urethral cancer. J Nucl Med 2010;51(suppl 2):1273
117. Kamel EM, Jichlinski P, Prior JO, et al: Forced diuresis improves the diagnostic accuracy of 18F-FDG-PET in abdominopelvic malignancies. J Nucl Med 2006;47:1803-1807 (Pubitemid 47545002)
118. Sun SS, Chang CH, Ding HJ, et al: Preliminary study of detecting urothelial malignancy with FDG-PET in Taiwanese ESRD patients. Anticancer Res 2009;29:3459-3463